Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will release its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The event will be accessible via a live webcast on the company's website, with an archived replay available within 24 hours.
Adaptive focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating various diseases, including cancer and autoimmune conditions.
- None.
- None.
SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
FAQ
When will Adaptive Biotechnologies report its Q3 2021 financial results?
What time is the conference call for Adaptive Biotechnologies' Q3 2021 results?
How can I access the webcast for Adaptive Biotechnologies' Q3 2021 earnings call?
Will there be a replay of Adaptive Biotechnologies' Q3 2021 earnings call?
